• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Italian Journal of Medicine >No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort
【24h】

No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort

机译：血管紧张素转化酶抑制剂或血管紧张素受体抑制剂在Covid-19患者中没有损害。医院队列前瞻性研究的结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study aims to assess the effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor inhibitors (ARBs) on the course of COVID-19. It is a prospective study on 221 (M/F ratio= 143/78, mean age 72±13) consecutive hypertensive patients with COVID-19: 76 (34.4%) treated with ACEIs, 63 (28.5%) with ARBs and 82 (37.1%) with antihypertensives OTHER than ACEIs or ARBs. They were all followed up until discharge or death. BAD outcome was defined as the need for invasive mechanical ventilation or death. The three classes of medication were well balanced for confounding variables. BAD outcome was overall recorded in 63/221 (28%) patients, in 20/76 (26%) of ACEI, in 17/63 (27%) of ARB and in 26/82 (32%) of OTHER users, with no statistically significant difference in any comparison. These findings refute the hypothesis that treatment with ACEIs or ARBs may negatively affect the course of COVID-19.
机译：本研究旨在评估血管紧张素转换酶抑制剂（Aceis）和血管紧张素受体抑制剂（ARB）在Covid-19过程中的影响。它是221（M / F比率= 143/78，平均72±13）连续高血压患者的前瞻性研究，Covid-19：76（34.4％）用Aceis治疗，63（28.5％）与ARBS和82（ 37.1％）与Aceis或Arbs以外的抗高血糖。他们都随后，直到排放或死亡。糟糕的结果被定义为需要侵入机械通气或死亡。三类药物适合混淆变量均衡。在63/221（28％）患者中，在acei的63/221（28％），在17/63（27％）的Arb，26/82（32％）其他用户中，有不良结果任何比较都没有统计学意义差异。这些发现反驳了与Aceis或Arbs治疗的假设可能会对Covid-19的过程产生负面影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号